Search research articles
Contact Us
Filters
Showing results (191-200 of 200) with videos related to
Page
of 20
Sort By:
You have reached the last page of results.
This site can display upto 200 results.
Bone Marrow Transplantation
|
April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee
Christopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
The Lancet. Haematology
|
June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Carmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Blood
|
July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
Blood
|
March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
Haematologica
|
December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Christian Michel, Andreas Burchert, Andreas Hochhaus, et al.
The Lancet. Haematology
|
October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Dietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Nature Medicine
|
April 11, 2018
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Nature Medicine
|
February 13, 2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Page
of 20
Search research articles
Search
Showing results (191-200 of 200) with videos related to
Sort By:
Page
of 20
You have reached the last page of results.
This site can display upto 200 results.
Bone Marrow Transplantation
|
April 1, 2026
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee
Christopher Armstrong, Kavita Raj, Giorgia Battipaglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
The Lancet. Haematology
|
June 4, 2026
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Carmelo Gurnari, Chris Armstrong, Giorgia Battipaglia, et al.
Blood
|
July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
Blood
|
March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT
Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
Haematologica
|
December 6, 2018
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Christian Michel, Andreas Burchert, Andreas Hochhaus, et al.
The Lancet. Haematology
|
October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Dietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Nature Medicine
|
April 11, 2018
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Nature Medicine
|
February 13, 2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Page
of 20